Clinipace secures $15M in Series C financing

Tuesday, September 27, 2011 12:34 PM

Clinipace Worldwide has closed a $15M Series C round of funding led by Morgan Stanley Expansion Capital of San Francisco, CA.  Existing investors, including Hatteras Venture Partners of Durham, NC, and Brook Private Equity Advisors of Boston, MA, also participated in this most recent round of funding.

Clinipace Worldwide plans to use the capital to continue building its therapeutic expertise and global capacity to deliver innovative technology-amplified contract research services.

"Clinipace is an innovative company with a strong management team and a clear vision.  When we looked at the successful adoption of its service model, combined with the robust and active segment which it serves, as well as overall macro-trends in life science R&D strategies, we realized now is the perfect time for Morgan Stanley Expansion Capital to support Clinipace’s efforts to strengthen its technology leadership, therapeutic expertise, and global reach,” said Melissa Daniels, managing principal, Morgan Stanley Expansion Capital.

Share:          
CWWeekly

February 23

Venture capital investors funding novel drug R&D three times more than companies repurposing, improving existing drugs

In appreciation: Karen Woodin will be remembered for her teaching, writing and lasting friendships

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs